VIRAMUNE XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8460704 | BOEHRINGER INGELHEIM | Extended release formulation of nevirapine |
Mar, 2029
(4 years from now) | |
Viramune Xr is owned by Boehringer Ingelheim.
Viramune Xr contains Nevirapine.
Viramune Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Viramune Xr was authorised for market use on 08 November, 2012.
Viramune Xr is available in tablet, extended release;oral dosage forms.
Viramune Xr can be used as treatment of hiv-1 by once daily administration.
The generics of Viramune Xr are possible to be released after 12 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 25, 2014 |
| New Patient Population(NPP) | Nov 08, 2015 |
Drugs and Companies using NEVIRAPINE ingredient
Market Authorisation Date: 08 November, 2012
Treatment: Treatment of hiv-1 by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of VIRAMUNE XR before it's drug patent expiration?
More Information on Dosage
VIRAMUNE XR family patents
